Q3 2026 results · 3 November 2026
Amgen's cholesterol drug Repatha passed $1bn as copycats cut Prolia by 45%.
$1.1Bsales of Repatha, Amgen's top drug
$632Mfrom Prolia, down 45% on biosimilars
$10.4Brevenue, up 8%
Source
Get a note when Amgen reports next.
Whatco sends a short notification with the number that matters, and the full story of the company is a tap away.
Download on the App Store
